Mirum Pharmaceuticals News and Activities
Presence
Mirum Pharmaceuticals develops and sells medicines for rare liver and digestive diseases. Its products and services support patients, healthcare providers, and specialty care centers that treat chronic and genetic conditions.
Mirum Pharmaceuticals products and services overview:
- Rare disease drugs
- Liver disease treatments
- Digestive disease treatments
- Prescription medicines
- Specialty care support
Revenue: ~$336 million
Employees: 500
Headquarters: Foster City, United States (USA)
Mirum Pharmaceuticals is one of the...
Mirum Pharmaceuticals is a company listed under the stock ticker MIRM (US).
Acquisition, funding and merger involving Mirum Pharmaceuticals.
- Mirum Pharmaceuticals has acquired Bluejay Therapeutics (posted on January 26 2026).
- Mirum Pharmaceuticals has announced the acquisition of Bluejay Therapeutics (posted on January 8 2026).
Executives
View the org chart displaying its 21 main executives
Most searched biographies at Mirum Pharmaceuticals
- Chris Peetz, Director, President and Chief Executive Officer
- Mike Grey, Executive Chairman of the Board
- Laurent Fischer, Director
Create your alert
to follow the executive moves at Mirum Pharmaceuticals.
Pharmaceuticals
Mirum Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Mirum Pharmaceuticals
- Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
- Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
- View more press releases Close
Social media about Mirum Pharmaceuticals
- Mirum Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Mirum Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
